기관회원 [로그인]
소속기관에서 받은 아이디, 비밀번호를 입력해 주세요.
개인회원 [로그인]

비회원 구매시 입력하신 핸드폰번호를 입력해 주세요.
본인 인증 후 구매내역을 확인하실 수 있습니다.

회원가입
서지반출
도토리 추출물 투여 후 갈산의 집단약동학 분석
[STEP1]서지반출 형식 선택
파일형식
@
서지도구
SNS
기타
[STEP2]서지반출 정보 선택
  • 제목
  • URL
돌아가기
확인
취소
  • 도토리 추출물 투여 후 갈산의 집단약동학 분석
저자명
이종태,도기찬,김지면,전상일,한승훈,Lee. Jong-Tae,Doh. Ki-Chan,Kim. Ji-Myon,Jeon. Sang-Il,Han. Seung-Hoon
간행물명
臨床藥理學會誌= The journal of Korean Society for Clinical Pharmacology and Therapeutics
권/호정보
2010년|18권 2호|pp.109-116 (8 pages)
발행정보
대한임상약리학회
파일정보
정기간행물|
PDF텍스트
주제분야
기타
이 논문은 한국과학기술정보연구원과 논문 연계를 통해 무료로 제공되는 원문입니다.
서지반출

기타언어초록

Background: Recently, researches on the pharmacological activity of natural substance are increasing. Acorn is one of promising candidates which is expected to exert anti-aging effects through anti-oxidant activity of gallic acid (GA). Methods: Crude extract was obtained from acorn which was harvested in Korea, 2009. After random allocation of 18 subjects into different dose groups (1g, 2g and 4g daily), the extract was given orally for 21 days. Full pharmacokinetic studies (0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hr after dose) were done after the first and last doses. The LC/MS/MS system was used to determine the GA in the extract and plasma samples. The results were analyzed using mixed effect methods NONMEM (Ver.6.2). Results: GA content in the extract was 0.27% (m/m). An one-compartment model was used to describe the PK property. Oral Clearance (CL/F) was 153 L/hr with the between-subject variability (BSV, as RSV %) of 44.5%. The estimated volume of distribution (V/F) was 231 L with the BSV of 37.0%. The population estimates of absorption rate constant (Ka) was $3.23;hr^{-1}$ and the relative bioavailability of 4g dose group was 75.4% compared to the other groups. Conclusion: Population pharmacokinetic parameters for gallic acid were successfully estimated. According to the parameters, it was expected that gallic acid would not be accumulated after repeated once-daily dosing and the extent of gallic acid absorption would be limited in the 4g dose group.